2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1780
Neoplasms
1500
Carcinoma, Non-Small-Cell Lung
1045
Prostatic Neoplasms
958
Colorectal Neoplasms
882
Lung Neoplasms
803
Pancreatic Neoplasms
573
Carcinoma, Hepatocellular
543
Leukemia, Myeloid, Acute
541
Stomach Neoplasms
513
Ovarian Neoplasms
508
Neoplasm Metastasis
499
Multiple Myeloma
494
Recurrence
412
Melanoma
387
Squamous Cell Carcinoma of Head and Neck
370
Brain Neoplasms
362
Uterine Cervical Neoplasms
361
Head and Neck Neoplasms
356
Esophageal Neoplasms
312
Precursor Cell Lymphoblastic Leukemia-Lymphoma
310
Lymphoma
306
Endometrial Neoplasms
305
Triple Negative Breast Neoplasms
299
Glioblastoma
299
Rectal Neoplasms
282
Sarcoma
266
Urinary Bladder Neoplasms
264
Hematologic Neoplasms
264
Colonic Neoplasms
255
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled